Amneal Completes Hat Trick With Delayed $2.6bn US Pegfilgrastim Entry
Developed With Kashiv BioSciences, Fylnetra Is Sixth Biosimilar On The Market
Executive Summary
With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.
You may also be interested in...
Amneal Outlines Ambitions To Become Leading Affordable Medicines Supplier In US
While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.
Amneal Submits Modest Guidance Raise Following Strong Second Quarter
Amneal now expects an additional $50m in net revenue this year, revising its revenue expectations up to between $2.3bn and $2.4bn following a successful second quarter.
Kashiv Eyeing Next Step As Xolair Biosimilar Passes Another Milestone
New Jersey-based biosimilar and 505(b)(2) specialist Kashiv Biosciences is in the race with multiple Xolair biosimilar sponsors, including frontrunner Celltrion.